 SAN DIEGO, Oct. 04, 2021 GLOBE NEWSWIRE -- Progenity, Inc. Progenity Nasdaq: PROG, an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Companys common stock, at a purchase price of 1.50 per share. The closing of the offering is expected to occur on or about October 6, 2021, subject to the satisfaction of customary closing conditions. 